UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
____________________
FORM
8-A
FOR
REGISTRATION OF CERTAIN CLASSES OF SECURITIES
PURSUANT
TO SECTION 12(b)
OR
12(g)
OF
THE
SECURITIES
EXCHANGE ACT OF 1934
|
Transdel
Pharmaceuticals, Inc.
|
|||||
|
(Exact
Name of Registrant as Specified in Its
Charter)
|
|
Delaware
|
45-0567010
|
|||||
|
(State
of Incorporation or Organization)
|
(I.R.S.
Employer Identification no.)
|
|||||
|
4225
Executive Square, Suite 460
La
Jolla, California
|
92037
|
|||||
|
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
|||||
|
If
this form relates to the registration of a class of securities pursuant
to
Section 12(b) of the Exchange Act and is effective pursuant to General
Instruction A.(c), please check the following box. o
|
If
this form relates to the registration of a class of securities pursuant
to
Section 12(g) of the Exchange Act and is effective pursuant to General
Instruction A.(d), please check the following box. x
|
|||||
|
Securities
Act registration statement file number to which this form
relates:
|
N/A
|
|
Securities
to be registered pursuant to Section 12(b) of the
Act:
|
|
Title
of each class
to
be so registered
|
Name
of each exchange on which
each
class is to be registered
|
|
|
N/A
|
N/A
|
|
|
Securities
to be registered pursuant to Section 12(g) of the Act:
|
|||||
|
Common
Stock, par value $0.001 per share
|
|||||
|
(Title
of Class)
|
|
Item
1.
|
Description
of Registrant’s Securities To Be Registered.
|
|
|
A
description of the common stock, par value $0.001 per share (the
“Common
Stock”) of Transdel Pharmaceuticals, Inc. (the “Company”) is contained in
Amendment No. 1 to the Company’s Registration Statement on Form SB-2 (File
No. 333-147930) filed with the Securities and Exchange Commission
on
December 27, 2007, including any amendment filed for the purpose
of
updating such description, which is incorporated by reference herein.
Any
form of prospectus or prospectus supplement to the Registration Statement
that includes such description of the Common Stock and that are
subsequently filed are hereby also incorporated by reference
herein.
|
||
|
Item
2.
|
Exhibits
|
|
|
The
following exhibits are filed as part of this Registration
Statement:
|
||
|
1
|
Amended
and Restated Certificate of Incorporation (incorporated herein by
reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed
with the Securities and Exchange Commission September 13,
2007)
|
|
|
2
|
Amended
and Restated Bylaws (incorporated herein by reference to Exhibit
3.2 to
the Company’s Current Report on Form 8-K filed with the Securities and
Exchange Commissions September 13,
2007)
|
|
-
1
-
SIGNATURE
Pursuant
to the requirements of Section 12 of the Securities Exchange Act of 1934, the
registrant has duly caused this Registration Statement to be signed on its
behalf by the undersigned, thereto duly authorized.
| Dated: December 27, 2007 |
Transdel
Pharmaceuticals, Inc.
|
|
| |
|
|
| By: |
/s/
John T. Lomoro
|
|
|
Name:
John
T. Lomoro
|
||
|
Title:
Chief
Financial Officer
|
||
-
2
-